Luo Xi, Sun Shiran, Xu Yi, Huang Xiaodong, Wang Kai, Wu Runye, Wang Jingbo, Zhang Ye, Zhang Jianghu, Chen Xuesong, Qu Yuan, Luo Jingwei, Yi Junlin
Department of Radiation Oncology National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100021,China.
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2023 Sep;37(9):708-714. doi: 10.13201/j.issn.2096-7993.2023.09.005.
This study aimed to evaluate the clinical features and treatment outcomes of the value of response-adapted treatment following radiotherapy and induction chemotherapy follwing subsequent comprehensive therapy in patients with resectable locally advanced hypopharyngeal carcinoma. This cohort study was conducted from September 2010 to September 2020 in our hospital, 231 patients pathologically confirmed stage Ⅲ and ⅣB resectable locally advanced hypopharyngeal carcinoma included. For the IC-directed ART strategy, IC is used to select good candidates to receive radical RT or CCRT, and others undergo surgery. He response-adapted strategy was determined based on the primary tumor response, which was evaluated at a dose of 50 Gy. If the response reached complete response or partial response(more than 80% tumor regression), patients received radical RT or CCRT; otherwise, they received surgery, if possible, at 4 to 6 weeks after RT. The end points of the study were OS(overall survival), progression free survival(PFS), locoregional recurrence-free survival(LRRFS) and LDFS. In IC-directed group, 75.0%(57/76) patients reached PR after 2 cycles of induction chemotherapy. While in RT-directed group, 70.3%(109/155) patients reached large PR at dose of 50 Gy. The median interquartile range follow-up period of the whole cohort was 63.8 months. The 5-year OS, PFS, LRRFS and SFL of the whole cohort were 47.9%、39.6%、44.3% and 36.2%, respectively. In evaluations based on the different treatment strategies, the 5-year OS and SFL were 51.3% versus 37.0%( 0.67; 95% 0.43-1.05; =0.07) and 27.8% versus 39.8%( 0.68; 95% 0.46-0.99; =0.04) between IC-directed and RT-directed groups. In additional, surgery complications did not significantly differ between these two groups. In this cohort study, the response-adapted strategy based on an early RT response facilitated better treatment tailoring, and higher laryngeal preservation compared with IC-directed strategies. This approach could provide a feasible laryngeal preservation strategy in patients with resectable locally advanced hypopharyngeal carcinoma.
本研究旨在评估在可切除的局部晚期下咽癌患者中,放疗后采用适应性反应治疗的价值以及诱导化疗后进行后续综合治疗的临床特征和治疗效果。本队列研究于2010年9月至2020年9月在我院进行,纳入了231例经病理证实为Ⅲ期和ⅣB期可切除的局部晚期下咽癌患者。对于以诱导化疗为导向的适应性反应治疗(ART)策略,诱导化疗用于选择合适的患者接受根治性放疗或同步放化疗,其他患者则接受手术。适应性反应策略根据原发肿瘤反应确定,在50 Gy剂量时进行评估。如果反应达到完全缓解或部分缓解(肿瘤消退超过80%),患者接受根治性放疗或同步放化疗;否则,如果可能,在放疗后4至6周接受手术。研究的终点为总生存期(OS)、无进展生存期(PFS)、局部区域无复发生存期(LRRFS)和无远处转移生存期(LDFS)。在以诱导化疗为导向的组中,75.0%(57/76)的患者在2周期诱导化疗后达到部分缓解。而在以放疗为导向的组中,70.3%(109/155)的患者在50 Gy剂量时达到大的部分缓解。整个队列的中位随访期(四分位间距)为63.8个月。整个队列的5年总生存期、无进展生存期、局部区域无复发生存期和无远处转移生存期分别为47.9%、39.6%、44.3%和36.2%。在基于不同治疗策略的评估中,以诱导化疗为导向的组和以放疗为导向的组之间的5年总生存期和无远处转移生存期分别为51.3%对37.0%(0.67;95%置信区间0.43 - 1.05;P = 0.07)和27.8%对39.8%(0.68;95%置信区间0.46 - 0.99;P = 0.04)。此外,两组之间的手术并发症无显著差异。在本队列研究中,基于早期放疗反应的适应性反应策略有助于更好地进行治疗调整,与以诱导化疗为导向的策略相比,保喉率更高。这种方法可为可切除的局部晚期下咽癌患者提供一种可行的保喉策略。